IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update
- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Collaboration with Atreca and BeiGene to discover, develop and manufacture novel …